普瑞巴林对原发性三叉神经痛患者血浆 P物质和降钙素基因相关肽的影响

摘要

目的：：观察普瑞巴林( PGB )和卡马西平( CBZ )对原发性三叉神经痛( PTN )患者血浆 P 物质( SP )和降钙素基因相关肽( CGRP)以及疼痛视觉模拟评分( VAS)的影响，评估PGB治疗PTN的疗效和安全性。方法：130例PTN患者随机分为观察组64例使用PGB治疗，对照组66例使用CBZ治疗。分别从低剂量开始给药，观察患者的疗效及不良反应至第4周末，两组患者在治疗前和结束时以放免法测定血浆SP和CGRP含量，并进行VAS评分。结果：观察组患者的总有效率89.1%，对照组72.1%，两组患者差异有统计学意义(P<0.05)；治疗后两组患者的血浆SP和CGRP均下降，观察组患者较对照组尤为明显(P<0.05)。观察组不良反应发生率31.3%明显低于对照组59.1%。结论：PGB治疗PTN疗效和安全性均高于CBZ。%Objective:To observe influence of Pregabalin ( PGB) and Carbamazepine ( CBZ) on plasma substance P ( SP) , calcitonin gene-related peptide ( CGRP) , and pain visual analogue score ( VAS) for patients with trigeminal neuralgia ( PTN) , and e﹣valuate efficacy and safety of PGB in treatment of PTN. Methods:130 patients with PTN were randomly divided into observation group ( PGB, 64 cases) and control group ( CBZ, 66 cases) . Both groups were administered with low dose at first, and then the therapeutic effect and adverse effect until termination of the fourth week were observed. The plasma SP and CGRP were detected by radioimmuno﹣assay before and after the treatment, while the visual analogue scales ( VAS) were measured. Results:The clinical efficiency of PGB was 89. 1%, that of CBZ was 72. 1%, and there was a significant difference between the two groups (P<0. 05). The treatments re﹣duced plasma SP and CGRP levels in both groups, and the change of PGB group was more obvious than that of CBZ group (P<0. 05). The incidence rate of adverse effect by PGB (31. 3%) was less than that by CBZ (59. 1%) (P<0. 05). Conclusions: The efficacy and safety of PGB for the patients with PTN are superior to those of CBZ.